Michael Myers
Tracked across 2 events · 13 articles · First seen Jul 09, 2026 · Last active Sep 08, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: As CEO of Quoin Pharmaceuticals, Dr. Michael Myers commented on the significance of the FDA clearance for patients with Peeling Skin Syndrome.
Jul 09, 2026 · 7 articles
Regulatory
On September 8, 2026, the U.S. United States — Food and Drug Administration granted Rare Pediatric Disease (RPD) Designation to Quoin Pharmaceuticals' lead asset, QRX003, for the treatment of Peeling Skin Syndrome (PSS). This is…
Impact: Michael Myers is the CEO of Quoin Pharmaceuticals and is quoted in the announcement, representing the company's leadership.
Sep 08, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Michael Myers live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard